What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Surgery
Christoph Bode mainly investigates Internal medicine, Cardiology, Surgery, Myocardial infarction and Percutaneous coronary intervention.
In his research on the topic of Internal medicine, Ciglitazone is strongly related with Endocrinology.
His work in the fields of Cardiology, such as Acute coronary syndrome, Angioplasty and Thrombus, intersects with other areas such as Placebo-controlled study.
The concepts of his Surgery study are interwoven with issues in Coronary artery disease and Unstable angina.
His Myocardial infarction study incorporates themes from Anesthesia and Clinical endpoint.
His Percutaneous coronary intervention research includes elements of Otamixaban, ST segment, Conventional PCI and Vitamin K antagonist.
His most cited work include:
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome (1333 citations)
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI (788 citations)
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes (585 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Surgery and Inflammation.
Internal medicine is frequently linked to Endocrinology in his study.
His Cardiology study frequently involves adjacent topics like Stroke.
Many of his studies involve connections with topics such as Randomized controlled trial and Myocardial infarction.
His studies in Inflammation integrate themes in fields like Adipose tissue, Receptor, Cancer research and Cell biology.
The study incorporates disciplines such as Endothelial stem cell and Bone morphogenetic protein in addition to Cell biology.
He most often published in these fields:
- Internal medicine (42.29%)
- Cardiology (29.81%)
- Myocardial infarction (12.61%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (42.29%)
- Cardiology (29.81%)
- Extracorporeal membrane oxygenation (5.86%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cardiology, Extracorporeal membrane oxygenation, Myocardial infarction and 2019-20 coronavirus outbreak are his primary areas of study.
His Internal medicine study often links to related topics such as Endocrinology.
He interconnects Stroke and Percutaneous in the investigation of issues within Cardiology.
His Extracorporeal membrane oxygenation research includes themes of Cardiogenic shock, ARDS, Cytokine and Pneumonia.
His Myocardial infarction study frequently draws parallels with other fields, such as Ischemia.
His work carried out in the field of Percutaneous coronary intervention brings together such families of science as Rivaroxaban, Randomized controlled trial, Conventional PCI and Vitamin K antagonist.
Between 2018 and 2021, his most popular works were:
- A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. (31 citations)
- Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score. (28 citations)
- Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. (26 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Surgery
The scientist’s investigation covers issues in Internal medicine, Cardiology, Extracorporeal membrane oxygenation, Platelet and Pneumonia.
In general Internal medicine, his work in Rivaroxaban, Randomized controlled trial and Percutaneous coronary intervention is often linked to In patient linking many areas of study.
The Randomized controlled trial study combines topics in areas such as Placebo and Clinical trial.
His Cardiology study combines topics from a wide range of disciplines, such as hERG and Risk factor.
Christoph Bode combines subjects such as Inflammation, Vulnerable plaque, Pharmacology and Microvesicles with his study of Platelet.
His Pneumonia research incorporates themes from Pulmonary embolism and Radiology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
